Genzyme Biosurgery's Focal Acquisition Boosts Biopolymer Presence
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Biosurgery's April 26 announcement that it will acquire the 78% of Focal, Inc. it does not already own for about $10 mil. in stock builds on an existing U.S. marketing agreement covering FocalSeal-L lung surgery sealant and further bolsters the company's presence in the biopolymers market.
You may also be interested in...
Confluent Eyes Untapped $200 Mil. Neurosurgery Market For DuraSeal
Confluent Surgical expects PMA approval by year-end for its DuraSeal sealant for prevention of cerebrospinal fluid (CSF) leaks in neurosurgery procedures, according to CEO Amar Sawhney
Confluent Eyes Untapped $200 Mil. Neurosurgery Market For DuraSeal
Confluent Surgical expects PMA approval by year-end for its DuraSeal sealant for prevention of cerebrospinal fluid (CSF) leaks in neurosurgery procedures, according to CEO Amar Sawhney
CryoLife BioGlue PMA Set For September Panel Review; BioDisc In Pipeline
Clinical data from a 151-patient, six-center trial comparing CryoLife's BioGlue surgical adhesive with standard sutures for cardiac and vascular repair is scheduled for FDA panel review Sept. 10-11.